Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: Intermediacy of nitric oxide and antioxidant defence mechanisms

FEBS Journal

Volumn 281, Issue 16, 2014, Pages 3719-3738

  Kanugula, Anantha Koteswararao ^a   Gollavilli, Paradesi Naidu ^a   Vasamsetti, Sathish Babu ^a   Karnewar, Santosh ^a   Gopoju, Raja ^a   Ummanni, Ramesh ^a   Kotamraju, Srigiridhar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

breast cancer; fluvastatin; invasion; iron; MnSOD; nitric oxide; transferrin receptor

Indexed keywords

AMINOTRIAZOLE; CATALASE; CD71 ANTIGEN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; GGTI 298; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; MEVALONIC ACID; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NITRIC OXIDE; SEPIAPTERIN; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; HYDROPHOBICITY; IRON BALANCE; IRON TRANSPORT; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

BREAST CANCER; FLUVASTATIN; H2O2; INVASION; IRON; MNSOD; NITRIC OXIDE; TRANSFERRIN RECEPTOR;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; INDOLES; IRON; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, TRANSFERRIN; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84906789772     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12893     Document Type: Article

References (63)

1. Nielsen SF, Nordestgaard BG, &, Bojesen SE, (2013) Statin use and reduced cancer-related mortality. N Engl J Med 368, 576-577.
2. Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, et al,. (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138, 499-508.
3. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al,. (2006) Breast cancer growth prevention by statins. Cancer Res 66, 8707-8714.
4. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, &, Porter JB, (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271, 20291-20299.
5. Lieu PT, Heiskala M, Peterson PA, &, Yang Y, (2001) The roles of iron in health and disease. Mol Aspects Med 22, 1-87.
6. Ponka P, Beaumont C, &, Richardson DR, (1998) Function and regulation of transferrin and ferritin. Semin Hematol 35, 35-54.
7. Toyokuni S, (1996) Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 20, 553-566.
8. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, et al,. (2003) The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5, 495-506.
9. Shindelman JE, Ortmeyer AE, &, Sussman HH, (1981) Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27, 329-334.
10. Walker RA, &, Day SJ, (1986) Transferrin receptor expression in non-malignant and malignant human breast tissue. J Pathol 148, 217-224.
11. Wrba F, Ritzinger E, Reiner A, &, Holzner JH, (1986) Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 410, 69-73.
12. Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Willingham MC, &, Pastan I, (1985) Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res 45, 751-757.
13. Trowbridge IS, &, Domingo DL, (1981) Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294, 171-173.
14. Yang DC, Jiang XP, Elliott RL, &, Head JF, (2001) Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res 21, 1777-1787.
15. Fukumura D, Kashiwagi S, &, Jain RK, (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6, 521-534.
16. Yim CY, McGregor JR, Kwon OD, Bastian NR, Rees M, Mori M, Hibbs JB Jr, &, Samlowski WE, (1995) Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J Immunol 155, 4382-4390.
17. Kotamraju S, Williams CL, &, Kalyanaraman B, (2007) Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 67, 7386-7394.
18. Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, &, Colburn NH, (2003) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2, 1285-1293.
19. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, &, Fidler IJ, (1995) Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181, 1333-1343.
20. Le X, Wei D, Huang S, Lancaster JR Jr, &, Xie K, (2005) Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its upregulation of protumor factors. Proc Natl Acad Sci USA 102, 8758-8763.
21. Pervin S, Singh R, &, Chaudhuri G, (2001) Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci USA 98, 3583-3588.
22. Szatrowski TP, &, Nathan CF, (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51, 794-798.
23. 2 levels, and its mechanism of action to induce growth in breast cancer cells: important roles of bioactive catalase and PP2A. Free Radic Biol Med 53, 1541-1551.
24. Du J, Sun C, Hu Z, Yang Y, Zhu Y, Zheng D, Gu L, &, Lu X, (2010) Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS ONE 5, e15940.
25. Petrat F, Rauen U, &, de Groot H, (1999) Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe, phen green SK. Hepatology 29, 1171-1179.
26. Clendening JW, Pandyra A, Boutros PC, El GS, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, et al,. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 107, 15051-15056.
27. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, &, Esserman LJ, (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17, 1028-1033.
28. Han HJ, Russo J, Kohwi Y, &, Kohwi-Shigematsu T, (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452, 187-193.
29. Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S, &, Kotamraju S, (2010) Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cells. Mol Med Rep 3, 857-861.
30. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, &, Lash TL, (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103, 1461-1468.
31. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, &, Chlebowski RT, (2006) Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98, 700-707.
32. Undela K, Srikanth V, &, Bansal D, (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135, 261-269.
33. Demierre MF, Higgins PD, Gruber SB, Hawk E, &, Lippman SM, (2005) Statins and cancer prevention. Nat Rev Cancer 5, 930-942.
34. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al,. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258.
35. Takai Y, Sasaki T, &, Matozaki T, (2001) Small GTP-binding proteins. Physiol Rev 81, 153-208.
36. Tang Y, Olufemi L, Wang MT, &, Nie D, (2008) Role of Rho GTPases in breast cancer. Front Biosci 13, 759-776.
37. Lamb JE, Ray F, Ward JH, Kushner JP, &, Kaplan J, (1983) Internalization and subcellular localization of transferrin and transferrin receptors in HeLa cells. J Biol Chem 258, 8751-8758.
38. Yu Y, &, Richardson DR, (2011) Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem 286, 15413-15427.
39. Hickok JR, Sahni S, Mikhed Y, Bonini MG, &, Thomas DD, (2011) Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J Biol Chem 286, 41413-41424.
40. Serbanovic-Canic J, Cvejic A, Soranzo N, Stemple DL, Ouwehand WH, &, Freson K, (2011) Silencing of RhoA nucleotide exchange factor, ARHGEF3, reveals its unexpected role in iron uptake. Blood 118, 4967-4976.
41. Rattan R, Giri S, Singh AK, &, Singh I, (2003) Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radic Biol Med 35, 1037-1050.
42. Kim S, &, Ponka P, (2003) Role of nitric oxide in cellular iron metabolism. Biometals 16, 125-135.
43. Mikhael MR, Soe-Lin S, Apte S, &, Ponka P, (2013) Nitrogen monoxide inhibits haem synthesis in mouse reticulocytes. Biochem J 451, 61-67.
44. Ambrosone CB, (2000) Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2, 903-917.
45. Emerit I, (1994) Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 16, 99-109.
46. Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, &, Walborg EF Jr, (1998) The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 (Suppl. 1), 289-295.
47. Storz P, (2005) Reactive oxygen species in tumor progression. Front Biosci 10, 1881-1896.
48. Kattan Z, Minig V, Leroy P, Dauca M, &, Becuwe P, (2008) Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 108, 203-215.
49. Hemmerlein B, Johanns U, Halbfass J, Bottcher T, Heuser M, Radzun HJ, &, Thelen P, (2004) The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide. Int J Oncol 24, 1069-1076.
50. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, &, Soria C, (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22, 1139-1148.
51. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, &, Kalyanaraman B, (2004) Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 279, 37575-37587.
52. 2-induced transferrin receptor-dependent apoptosis in endothelial cells: role of ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 100, 10653-10658.
53. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, &, Kalyanaraman B, (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277, 17179-17187.
54. Kotamraju S, Hogg N, Joseph J, Keefer LK, &, Kalyanaraman B, (2001) Inhibition of oxidized low-density lipoprotein-induced apoptosis in endothelial cells by nitric oxide. Peroxyl radical scavenging as an antiapoptotic mechanism. J Biol Chem 276, 17316-17323.
55. Tampo Y, Kotamraju S, Chitambar CR, Kalivendi SV, Keszler A, Joseph J, &, Kalyanaraman B, (2003) Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis. Circ Res 92, 56-63.
56. Richardson DR, Neumannova V, Nagy E, &, Ponka P, (1995) The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Blood 86, 3211-3219.
57. Haendeler J, Hoffmann J, Zeiher AM, &, Dimmeler S, (2004) Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 110, 856-861.
58. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, &, Torti SV, (2014) IRP2 regulates breast tumor growth. Cancer Res 74, 497-507.
59. Vichai V, &, Kirtikara K, (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1, 1112-1116.
60. Ramachandran A, Ceaser E, &, Darley-Usmar VM, (2004) Chronic exposure to nitric oxide alters the free iron pool in endothelial cells: role of mitochondrial respiratory complexes and heat shock proteins. Proc Natl Acad Sci USA 101, 384-389.
61. 2 formation. FASEB J 14, 1953-1964.
62. Wagner BA, Evig CB, Reszka KJ, Buettner GR, &, Burns CP, (2005) Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells. Arch Biochem Biophys 440, 181-190.
63. Hissin PJ, &, Hilf RA, (1976) fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74, 214-226.